CSL | Jotup

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Retrieved on:

Friday, September 13, 2024

Ministry of Health, Ministry, CSL, Therapy, Safety, Arcturus Therapeutics, COVID-19, Vaccine, Messenger, Senior, Public, World Health Organization, Risk, Arcturus, ASX, SAN, Vaccination, Immunity

KING OF PRUSSIA, Pa. and SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) granted approval and authorization for their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older.

Key Points:

The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older.
CSL's exclusive partner in Japan, Meiji Seika Pharma, will begin distributing the updated vaccine in time for the October COVID-19 vaccination campaign, marking the world's first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older.
"We look forward to introducing KOSTAIVE® in Japan as a safe, tolerable and more durable option in protecting against COVID-19."
"We look forward to continuing to work with CSL and regulators to explore the development of KOSTAIVE® in additional countries."

Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Retrieved on:

Friday, September 13, 2024

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) granted approval and authorization for their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®.

Key Points:

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) granted approval and authorization for their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®.
The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older.
CSL's exclusive partner in Japan, Meiji Seika Pharma, will begin distributing the updated vaccine in time for the October COVID-19 vaccination campaign, marking the world's first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older.
“We look forward to continuing to work with CSL and regulators to explore the development of KOSTAIVE® in additional countries.”

Helen Badger joins Critical IoT Connectivity leaders CSL Group as Marketing Director

Retrieved on:

Thursday, September 12, 2024

Growth, Canada Steamship Lines, Critical, IRIS, Router, Marketing, CSL, Mobile phone

LONDON, Sept. 12, 2024 /PRNewswire/ -- CSL Group, the market leader in IoT connectivity solutions, is pleased to announce the appointment of Helen Badger as Marketing Director.

Key Points:

LONDON, Sept. 12, 2024 /PRNewswire/ -- CSL Group, the market leader in IoT connectivity solutions, is pleased to announce the appointment of Helen Badger as Marketing Director.
Helen's expertise in strategic marketing, brand management, and digital transformation will be instrumental as CSL Group continues to innovate and expand its services, supporting critical connectivity solutions across multiple verticals.
Helen Badger's leadership will play a pivotal role in ensuring that customers navigate the complexities of IoT connectivity with ease.
Helen Badger commented, "I am thrilled to join CSL Group at such an exciting time in the industry.

Helen Badger joins Critical IoT Connectivity leaders CSL Group as Marketing Director

Retrieved on:

Thursday, September 12, 2024

Growth, Canada Steamship Lines, Critical, IRIS, Router, Marketing, CSL, Mobile phone

LONDON, Sept. 12, 2024 /PRNewswire/ -- CSL Group, the market leader in IoT connectivity solutions, is pleased to announce the appointment of Helen Badger as Marketing Director.

Key Points:

LONDON, Sept. 12, 2024 /PRNewswire/ -- CSL Group, the market leader in IoT connectivity solutions, is pleased to announce the appointment of Helen Badger as Marketing Director.
Helen's expertise in strategic marketing, brand management, and digital transformation will be instrumental as CSL Group continues to innovate and expand its services, supporting critical connectivity solutions across multiple verticals.
Helen Badger's leadership will play a pivotal role in ensuring that customers navigate the complexities of IoT connectivity with ease.
Helen Badger commented, "I am thrilled to join CSL Group at such an exciting time in the industry.

Corn Steep Liquor (CSL) Business Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on:

Tuesday, August 20, 2024

Agriculture, Biotechnology, Natural Resources, Health, Chemicals, Plastics, Technology, Agritech, Manufacturing, Growth, Consumer behaviour, CSL, Organic, Convention (norm), Fermentation, Corn steep liquor, Biofuel, Global Bio-Chem

The "Corn Steep Liquor (CSL) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Corn Steep Liquor (CSL) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Corn Steep Liquor (CSL) is estimated at US$3.1 Billion in 2023 and is projected to reach US$3.7 Billion by 2030, growing at a CAGR of 2.4% from 2023 to 2030.
This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the Corn Steep Liquor market is driven by several factors, including advancements in biotechnology that increase the demand for cost-effective and efficient fermentation substrates.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRDI, BALY, CGBD on Behalf of Shareholders

Retrieved on:

Friday, August 9, 2024

Advertising, CSL, Sale, Fraud, Security (finance)

If you are a GRIID shareholder, click here to learn more about your rights and options .

Key Points:

If you are a GRIID shareholder, click here to learn more about your rights and options .
If you are a CGBD shareholder, click here to learn more about your rights and options .
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

CARLYLE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Carlyle Secured Lending, Inc. - CGBD

Retrieved on:

Thursday, August 8, 2024

Class Action Lawsuit, Professional Services, Legal, KSF, CSL

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Carlyle Secured Lending, Inc. (the “Company”) (NasdaqGS: CGBD) and Carlyle Secured Lending III (“CSL III”).

Key Points:

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Carlyle Secured Lending, Inc. (the “Company”) (NasdaqGS: CGBD) and Carlyle Secured Lending III (“CSL III”).
Under the terms of the proposed transaction, CSL III shareholders will receive shares of CGBD based on a ratio determined shortly before the closing of the merger.
KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company’s shareholders.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Retrieved on:

Monday, August 5, 2024

“We are pleased to remain on track for our first commercial product launch of Kostaive® in Japan later this year,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points:

“We are pleased to remain on track for our first commercial product launch of Kostaive® in Japan later this year,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
In June, Arcturus presented Phase 1 interim data of ARCT-032 at the 47th Annual European Cystic Fibrosis Conference.
The increase was primarily due to the CSL agreement during the second quarter of 2024.
The expected cash runway extends approximately three years based on the current pipeline and programs through the first quarter of fiscal year 2027.

CGBD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Carlyle Secured Lending, Inc. Is Fair to Shareholders

Retrieved on:

Monday, August 5, 2024

Class Action Lawsuit, Professional Services, Legal, Advertising, CSL, Fraud

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Carlyle Secured Lending, Inc. (NASDAQ: CGBD) and Carlyle Secured Lending III (“CSL III”) is fair to CGBD shareholders.

Key Points:

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Carlyle Secured Lending, Inc. (NASDAQ: CGBD) and Carlyle Secured Lending III (“CSL III”) is fair to CGBD shareholders.
Under the terms of the proposed transaction, CSL III shareholders will receive shares of CGBD based on a ratio determined shortly before the closing of the merger.
On behalf of CGBD shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Carlyle Secured Lending, Inc. Announces Merger with Carlyle Secured Lending III

Retrieved on:

Monday, August 5, 2024

Sullivan & Cromwell, NAV, Tax, Investment, Risk, Trustee, Sidley Austin, Keefe, Bruyette & Woods, Par value, EST, COVID, Depreciation, NII, Oliver Cromwell, CSL, Security (finance)

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, “we,” “us,” “our,” “CGBD” or the “Company”) (NASDAQ: CGBD), a business development company focused on directly-originated lending to sponsor-backed U.S. middle market companies, has entered into a definitive agreement to acquire Carlyle Secured Lending III (“CSL III”), a private business development company with a similar investment strategy and portfolio. The stock-for-stock transaction will have a floating exchange ratio that has the potential to allow CGBD and CSL III to share the benefits if CGBD is trading above NAV shortly before merger close. Following closing, CGBD is expected to have total assets of over $2.5 billion and net assets of over $1.2 billion.1

Key Points:

There is strong momentum across our direct lending franchise, and we believe bringing CGBD and CSL III together will enable us to build on that momentum.”
In order to enhance the benefits of the transaction for stockholders, Carlyle Investment Management L.L.C.
(“CIM”), a wholly owned subsidiary of Carlyle, has agreed to exchange its shares of CGBD convertible preferred stock for CGBD common stock.
The CGBD convertible preferred stock was issued by CGBD as part of an investment Carlyle made to support CGBD during the market dislocation resulting from the COVID pandemic.
The conference call will be available via public webcast via a link on Carlyle Secured Lending’s website and will also be available on our website soon after the call’s completion.